NewAmsterdam Pharma terminates $150M ATM equity offering program

NewAmsterdam Pharma Co N.V.

Company delivered notice to Cowen and TD Cowen to suspend and terminate ATM prospectus supplement dated August 9, 2024.
Program allowed for sale of up to $150M of ordinary shares.
No sales will be made under Sales Agreement until new prospectus or registration statement is filed.
Sales Agreement remains in full force and effect other than the terminated ATM prospectus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.